Last reviewed 2026-04-20 · How we verify

Pf-07284890 (pf-07284890)

At a glance

Approved indications

• Multiple Myeloma
• Relapsed or Refractory Multiple Myeloma
• Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy
• Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy
• Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy
• Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor
• Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent
• Relapsed or Refractory Multiple Myeloma after at least 1 line of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody
• Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor
• Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent
• Relapsed or Refractory Multiple Myeloma after at least 2 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody
• Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor
• Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent
• Relapsed or Refractory Multiple Myeloma after at least 3 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody
• Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy
• Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor
• Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent
• Relapsed or Refractory Multiple Myeloma after at least 4 lines of therapy and a proteasome inhibitor and an immunomodulatory agent and a CD38-directed monoclonal antibody
• Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy
• Relapsed or Refractory Multiple Myeloma after at least 5 lines of therapy and a proteasome inhibitor

Common side effects

No common side effects on file.

Drug interactions

• Warfarin
• P-glycoprotein inhibitors
• P-glycoprotein inducers
• Strong CYP3A4 inhibitors
• Strong CYP3A4 inducers

Key clinical trials

• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement (PHASE1)
• A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Pf-07284890 CI brief — competitive landscape report
• Pf-07284890 updates RSS · CI watch RSS
• Pfizer portfolio CI